MiNK Therapeutics, Inc.

INKT Nasdaq SEC CIK 1840229
Follow MiNK Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $200K
Net income −$2.6M +11.6% vs same quarter last year
EPS, diluted −$0.50 +23.1% vs same quarter last year
Operating cash flow −$1.3M −35.5% vs same quarter last year
Revenue by quarter
$0
$200K
Q3 25 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$12.5M
FY24−$10.8M
FY23−$22.5M
FY22−$28M
FY21−$30.2M
FY20−$16.2M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$15.8M
FY22−$19.1M
FY21−$13.1M
FY20−$8.4M
FY19-